Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment-Reference-Cited by-同舟云学术

Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment

Published:2021-05 Issue: Volume:Volume 13 Page:4041-4053
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Tong Jingtao^ORCID,Mao Yifei,Yang Ziru,Xu Quan,Zheng Zhen,Zhang Hui,Wang Jingjing,Zhang Sandian,Rong Weibo,Zheng Lu^ORCID

Publisher

Informa UK Limited

Subject

Oncology

Reference33 articles.

1. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

2. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

3. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

4. Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy;Immunotherapy;2024-08-06

2. Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors;Journal of Immunotherapy;2024-07-11

3. Prognostic models for immunotherapy in non-small cell lung cancer: A comprehensive review;Heliyon;2024-04

4. Optimization of the tandem enzyme activity of V-MOF and its derivatives for highly sensitive nonenzymatic detection of cholesterol in living cells;Journal of Colloid and Interface Science;2023-11

5. Nomogram for predicting the prognosis of metastatic colorectal cancer patients treated with anti-PD1 therapy based on serum lipids analysis;Cancer Immunology, Immunotherapy;2023-08-17